Menu Search
Equities

Telix Pharmaceuticals Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
T3X:MUN

Telix Pharmaceuticals Ltd

Actions
  • Price (EUR)5.20
  • Today's Change-0.098 / -1.85%
  • Shares traded650.00
  • 1 Year change-68.62%
  • Beta1.5830
Data delayed at least 15 minutes, as of Feb 16 2026 07:06 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.

  • Revenue in AUD (TTM)941.37m
  • Net income in AUD15.65m
  • Incorporated2017
  • Employees234.00
  • Location
    Telix Pharmaceuticals Ltd55 Flemington Road, North MelbourneMELBOURNE 3051AustraliaAUS
  • Phone+61 39093-3855
  • Websitehttps://telixpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.